Survodutide | 10 vials
Survodutide (development code BI 456906) is a novel synthetic peptide and dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) . It is conceptually based on the endogenous gut hormone oxyntomodulin, engineered for enhanced potency and extended half-life .
Key Specifications:
-
UNII: 2ALA66NS64
-
CAS Number: 2805997-46-8
-
Synonyms: BI 456906, BI-456906
-
Molecular Formula: Not specified in search results (large peptide)
-
Molecular Weight: Not specified in search results
-
Developers: Boehringer Ingelheim and Zealand Pharma
-
Administration: Once-weekly subcutaneous injection
Mechanism of Action:
Survodutide is a 29-amino acid peptide derived from glucagon, with the incorporation of potent GLP-1 activities . Key features include:
-
Dual receptor agonism: Simultaneously activates both glucagon receptors (GCGR) and GLP-1 receptors (GLP-1R)
-
Enhanced weight loss: The glucagon agonist component drives energy expenditure, while the GLP-1 component reduces appetite and increases satiety
-
Extended half-life: Contains a C18 diacid which mediates binding to albumin, enabling once-weekly dosing
-
Direct hepatic effects: Glucagon agonism may directly impact liver metabolism, contributing to improvements in fibrosis
Key Research Applications:
| Category | Applications |
|---|---|
| Obesity/Weight Management | Phase 3 trials ongoing (SYNCHRONIZE program); up to 19% weight loss in Phase 2 trials |
| Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 3 trials ongoing (LIVERAGE program); FDA Breakthrough Therapy designation (Oct 2024) |
| Type 2 Diabetes | Significant HbA1c reduction demonstrated in meta-analyses |
| Cardiovascular Research | Phase 3 CVOT (SYNCHRONIZE-CVOT) ongoing in patients with obesity and high CV risk |
| Liver Fibrosis | Phase 2 data showed improvement in MASH without worsening fibrosis in 83% of participants |
Clinical Efficacy Summary:
| Parameter | Finding | Source |
|---|---|---|
| Weight loss | Up to 18.7% at 46 weeks (dose-dependent); 40% achieved ≥20% loss | |
| MASH improvement | 83% achieved histologic remission vs. 18.2% placebo | |
| Liver fat reduction | ≥30% reduction in up to 87% of participants | |
| HbA1c reduction | Mean difference -0.66% to -0.88% vs. placebo | |
| Blood pressure | Reduction up to 8.6 mmHg systolic, 4.8 mmHg diastolic |
Regulatory Status:
| Authority | Status | Date |
|---|---|---|
| FDA | Breakthrough Therapy Designation (MASH with fibrosis) | October 2024 |
| FDA | Fast Track Designation | 2021 |
| Clinical development | Phase 3 (obesity, MASH, CVOT) | Ongoing |
Important Notice:
FOR RESEARCH USE ONLY. NOT FOR HUMAN USE, THERAPEUTIC, OR DIAGNOSTIC APPLICATIONS.
Select Option & Quantity
Key Benefits
- High purity research compound (>98%)
- Third-party tested and verified
- Lyophilized for maximum stability
- Certificate of analysis available
